Streamex Corp美股招股说明书(2026-01-22版)

Filed Pursuant to Rule 424(b)(5)Registration No. 333-276298 Subject to Completion, dated January 22, 2026 Preliminary Prospectus Supplement(To Prospectus dated December 17, 2024) Streamex Corp. Shares of Common Stock We are offeringshares of our common stock, par value $0.001 per share. Our common stock is traded on the Nasdaq Capital Market under the symbol “STEX.” On January 21, 2026, the last reported saleprice of our common stock on the Nasdaq Capital Market was $3.08 per share. Investing in our securities involves a high degree of risk. Before buying any securities, you should review carefully the risksand uncertainties described under the heading “Risk Factors” beginning on page S-12of this prospectus supplement, on page 5 of theaccompanying prospectus and in the documents incorporated by reference into this prospectus supplement and theaccompanying (1)We have agreed to reimburse the underwriters for certain offering-related expenses. See “Underwriting” beginning on page S-20 of thisprospectus supplement for additional information regarding underwriting discounts, commissions and estimated expenses. We have granted the underwriters an option to purchase up to an additionalshares of our common stock at the public offeringprice, less the underwriting discount, for 30 days after the date of this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securitiesor determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to thecontrary is a criminal offense. The underwriters expect to deliver the shares on or about JanuaryJoint Book-Running Managers Siebert The date of this prospectus supplement is January ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the terms of the offering and also adds toand updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectussupplement and the accompanying prospectus. The second part consists of a prospectus dated December 17, 2024, included in the registrationstatement on Form S-3 (File No. 333-276298) that we filed with the U.S. Securities and Exchange Commission (the “SEC”) under the Generally, when we refer to this “prospectus,” we are referring to both documents combined. If information in this prospectussupplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. In addition, to the extent there isa conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in any documentincorporated by reference that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the This prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein,describe the specific terms of this offering. We urge you to carefully read this prospectus supplement and the accompanying prospectus, and thedocuments incorporated by reference herein and therein, before buying any of the securities being offered under this prospectus supplement.This prospectus supplement may add to or update information contained in the accompanying prospectus and the documents incorporated byreference therein. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in the You should rely only on the information contained in this prospectus supplement and the accompanying prospectus or incorporated byreference herein or therein or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We have not, and the underwriters have not, authorized anyone to provide any information or to make any representationsother than those contained in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses preparedby or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide noassurance as to the reliability of, any other information that others may give you. This prospectus supplement is an offer to sell only thesecurities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained inthis prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein or in anyapplicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit thisoffering or possession or distribution of this prospectus supplement, the accompanying prospectus or any free wr